There were no clinically considerable variations in the pharmacokinetics of both midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when employed concomitantly with finerenone. Various doses of 40 mg finerenone once-each day had no clinically suitable effect on AUC or Cmax with the BCRP